Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.

Trial Details

NCT ID
NCT05626400
Phase
NA
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Senl-T7
Locations (sample)
  • Beijingcun, Hebei, China|41.26103,119.10946

Key Eligibility Criteria

  • Diagnosis of relapsed/refractory T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma: Induction therapy failed to achieve a complete rem…
  • CD7 expression in tumor cells was detected by flow cytometry；
  • Life expectancy greater than 12 weeks；
  • KPS or Lansky score≥60;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →